Cancer survivor follow-up labs: what to track and why
Anchor biomarkers: CBC, CMP, TSH, Lipid panel, HbA1c, Vitamin D
TL;DR
- •Survivorship labs are longitudinal, not single-snapshot. What matters is the trajectory across years — not whether today's value sits inside a reference range.
- •The labs you track depend on three things: the original cancer type, the treatments you received, and the side effects those treatments leave behind.
- •General-health labs (CBC, CMP, inflammation, metabolic) matter too — many cancer treatments cause cardiometabolic, endocrine, and hematologic late effects that don't show up unless you specifically watch for them.
The baseline survivorship panel — what each general marker tells you
| Marker | Reference range | What it means |
|---|---|---|
| CBC (complete blood count) | Varies by component | Catches cytopenias (treatment-related), secondary blood cancers (rare but real), and anemia. |
| CMP (comprehensive metabolic panel) | Varies | Kidney function (creatinine, eGFR), liver function (ALT, AST), electrolytes, glucose. Many treatments affect these. |
| TSH + free T4 | TSH ~0.4 – 4.0 mIU/L | Thyroid is affected by neck/chest radiation, some immunotherapies, and is independently common in survivor populations. |
| Lipid panel + ApoB + Lp(a) | Optimal (risk-dependent) | Cardiometabolic risk often accelerated by treatments and by relative inactivity during treatment. |
| HbA1c, fasting insulin | HbA1c < 5.7% | Steroid courses during chemotherapy can predispose to insulin resistance. |
| Vitamin D | > 30 ng/mL | Frequently low; matters for bone health (especially with aromatase inhibitors or steroid courses). |
| B12, folate | Adequate | Often suboptimal in survivorship populations. |
| Ferritin / iron studies | Adequate | Anemia is common; iron status guides workup. |
| hs-CRP, ESR | hs-CRP < 3 mg/L | Chronic low-grade inflammation has prognostic implications. |
| BNP / NT-proBNP | Varies by age | Worth tracking for cardiotoxin-exposed survivors (e.g., anthracyclines). |
| Bone density (DEXA) | T-score > –1.0 | Many treatments accelerate bone loss; baseline + repeat scans warranted. |
Cancer-specific surveillance markers (PSA, CEA, CA-125, thyroglobulin, AFP / β-hCG, and others) are driven entirely by your cancer type, stage, and treatment, and their schedules must be set by your oncology team. This page covers the general-health baseline that survivorship guidelines recommend alongside cancer-specific monitoring.
Three real patterns Phi Longevity has seen
Example patterns · synthetic data drawn from Phi Longevity's scenario library. Not real patient records.
Pattern 1 — Breast cancer survivor on an aromatase inhibitor, 3 years post-treatment.
CBC normal. CMP normal. TSH normal. Lipid panel: LDL 142, HDL 48, ApoB 105 (rising from prior baselines). HbA1c 5.7 (rising). Vitamin D 22 (low). DEXA: T-score –1.8 (osteopenia). The trajectory: aromatase inhibition + reduced activity + treatment-era weight changes are creating cardiometabolic and bone-health concerns that the cancer-surveillance panels miss. An integrated review surfaces all three concerns at once — for the conversation with the oncology and primary-care teams.
Example pattern · synthetic data
Pattern 2 — Colorectal cancer survivor, 2 years post-treatment, no recurrence.
CEA stable < 2.0 across all post-treatment checks. CBC normal. CMP: creatinine 1.1 (was 0.9 pre-treatment, mild residual platinum effect). Magnesium 1.6 (low — platinum effect persists). HbA1c 6.0 (creeping). Lipid panel deteriorating. The read: cancer surveillance is reassuring; the general-health trajectory needs attention. Magnesium repletion and metabolic follow-up are worth raising with the care team.
Example pattern · synthetic data
Pattern 3 — Hodgkin lymphoma survivor, 12 years post-treatment.
Long-term remission. TSH 5.8 (mildly elevated — radiation-induced thyroid effect emerging). Lipid panel: ApoB 110, Lp(a) elevated genetic baseline. Echocardiogram: mild diastolic dysfunction (anthracycline late effect, mild). Bone density normal. A decade out, the pattern across late effects becomes the focus; the cancer itself is increasingly background, and the cardiovascular and endocrine late effects move to the foreground.
Example pattern · synthetic data
Questions to bring to your doctor
- Given my specific cancer type and treatments, what is the recommended cancer-surveillance schedule and which markers do you monitor?
- What late effects from my treatments should I be specifically watching for, and at what intervals?
- Should I have a survivorship care plan document I can take to my primary care doctor and any other specialists?
- What's my baseline for general cardiometabolic risk — lipids, glucose, blood pressure — and what should the trajectory look like?
- Should I have a baseline echocardiogram and follow-up imaging given my treatment history?
- What's my bone density status, and when should we repeat DEXA?
- Are there specific dietary, exercise, or supplement approaches that have data in my specific survivorship context?
What Phi Longevity adds beyond a single number
Survivorship monitoring spans years and multiple specialties. Most patients have lab values scattered across oncology, primary care, cardiology, endocrinology, and others — and no single provider is looking at all of them in one place. Phi pulls every panel you upload into a single integrated longitudinal view: cancer-specific markers, treatment-late-effects monitoring, and general-health labs together, across the entire post-treatment period. The integrated picture supports the conversation with your oncology team and your primary care — it does not replace cancer follow-up care; it helps you organize and understand the data that follow-up care generates.
Frequently asked questions
How long do I need to be monitored after cancer treatment?
It depends on cancer type. Many cancers have intensive surveillance for the first 2–5 years, then less frequent monitoring. Some (breast, prostate, certain hematologic) warrant lifelong monitoring at various intervals. Your oncology team should set the schedule.
What's a "survivorship care plan"?
A document summarizing your diagnosis, treatments received, completion dates, and recommended follow-up. The National Cancer Institute, ASCO, and many cancer centers have templates. If you don't have one, ask for it — primary care providers and future specialists will need it.
Will my insurance keep covering surveillance labs?
Generally yes, when ordered as appropriate cancer follow-up. Some labs (e.g., advanced lipid panels, vitamin D) may not be covered as part of cancer follow-up specifically and may need to be ordered through primary care.
Are tumor markers reliable?
Tumor markers (CEA, CA-125, AFP, PSA, and others) are variably reliable depending on the cancer. They're best for tracking trends in patients with known disease, less useful for screening. False positives and false negatives are real — interpretation requires oncology context.
Should I worry about a second cancer?
Cancer survivors do have elevated risk of certain second cancers, both from shared risk factors and from treatments themselves. The specific risk depends on the original cancer and treatments. Survivorship guidelines incorporate appropriate second-cancer screening.
What's the role of lifestyle after cancer treatment?
Substantial. Physical activity, dietary patterns, weight management, sleep, and limiting alcohol all have data supporting improved survival, lower recurrence risk for some cancers, and better quality of life. The American Cancer Society and major oncology organizations publish post-treatment lifestyle guidelines.
My oncologist says "you're done — you don't need to see me anymore." Is that right?
Discharge timing varies. Some cancers are appropriately handed fully back to primary care after 5 years. Others (breast, prostate, certain hematologic) often involve longer oncology touchpoints. If you're being discharged, make sure you have a clear written follow-up plan and a primary care doctor who has the survivorship-care document.
References
All citations verified against PubMed / publisher of record 2026-05-25.
- 1.Armenian SH, Lacchetti C, Barac A, et al. (2017). Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. 35(8):893-911. — ASCO standard for anthracycline / trastuzumab / radiation-related cardiac surveillance in adult cancer survivors.PubMed →DOI →
- 2.Brahmer JR, Lacchetti C, Schneider BJ, et al. (2018). Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. 36(17):1714-1768. — Joint ASCO/NCCN reference for immune-related adverse events from checkpoint inhibitors (TSH, ACTH/cortisol, autoimmune-style endocrine late effects).DOI →
- 3.NCCN Guidelines for Management of Immunotherapy-Related Toxicities (annual updates). National Comprehensive Cancer Network. — Companion clinical-practice reference for immunotherapy-related-toxicity management; updated annually (registration required).DOI →
- 4.NCCN Survivorship Guidelines (annual updates). National Comprehensive Cancer Network. — Standard reference for survivorship-care framework (registration required).DOI →
- 5.ASCO Survivorship Care Guidelines (multiple guidelines by cancer type). American Society of Clinical Oncology. — Cancer-specific survivorship recommendations (breast, colorectal, prostate, head and neck, lung).DOI →
This page is general educational content. Cancer-specific surveillance protocols (e.g., PSA for prostate, CEA for some colorectal cancers, thyroglobulin for thyroid, CA-125 for ovarian, AFP / β-hCG for germ-cell tumors) come from the cancer-specific ASCO and NCCN survivorship guidelines, which vary by cancer type and patient context. Phi is not a substitute for cancer follow-up care; it's a tool to help you organize and understand the data that follow-up care generates. Every link above opens in a new tab.
By Steve Pinedo
Co-founder, Phi Longevity
Last updated: 2026-07-13
Steve Pinedo is the Co-founder of Phi Longevity, the AI application that turns a confusing stack of lab reports, wearable data, and clinical notes into a single, integrated picture of your health. He started Phi Longevity to make proactive health and wellness far easier to achieve. He realized how difficult it was for clients to manage their own care, records and coordination so he assembled a comprehensive M.D. led clinical team behind the platform, packaging the proactive-care experience that delivered measurable outcomes (lower triglycerides, reduced body fat, improved LDL, balanced hormones, relief from long-running autoimmune conditions) for any patient with a complicated lab to use now with an application. More about Phi Longevity →